Clinical Trial Results: A Safety and Antitumor Activity Trial of Immunoradiotherapy Combinations as a Treatment Option for Subjects With Metastatic Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating immunoradiotherapy combinations in metastatic solid tumors; study terminated with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-cns Tumor

Drugs mentioned

• Immunoradiotherapy combinations

Snippet

Sponsor: Genmab | Conditions: Non-CNS Tumor | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2026-07-02